XML 43 R33.htm IDEA: XBRL DOCUMENT
v3.23.1

Research Collaboration and License Agreements - Additional Information (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Nov. 30, 2017 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2018 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Jul. 31, 2021 | Jun. 30, 2019
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  | $ 10,100,000 | $ 12,100,000 |  |  | $ 10,700,000 | $ 12,500,000 |  |
Collaboration contract asset and other assets |  | 10,300,000 |  |  |  | $ 10,800,000 |  |  |
Revenue adjustments arising from contract modifications |  | (8,200,000) |  |  |  |  |  |  |
Pfizer, Inc. |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Payments received |  | 1,000,000 | 3,500,000 | $ 28,000,000 |  |  |  |  |
Pfizer, Inc. | Regulatory and Sales-Based Milestones | Maximum |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  |  |  | $ 1,400,000,000 |
Pfizer, Inc. | Collaboration Agreement |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  |  |  | 650,000,000 |
Collaboration agreement direct and incremental costs incurred |  | 12,900,000 |  |  |  |  |  |  |
Collaboration contract asset and other assets |  | 12,900,000 |  |  |  |  |  |  |
Pfizer, Inc. | Regulatory Milestone Related to Marketing Approvals |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  |  |  | 400,000,000 |
Payments received |  | 0 |  |  |  |  |  |  |
Pfizer, Inc. | Sales-Based Milestones |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  |  |  | $ 1,000,000,000 |
Pfizer, Inc. | Development Milestone Payments | Maximum |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  | 225,000,000 |  |  |  |  |  |  |
Pfizer, Inc. | Sales Based Milestone Payments |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Payments received |  | 0 |  |  |  |  |  |  |
Pfizer, Inc. | Sales Based Milestone Payments | Maximum |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  | 550,000,000 |  |  |  |  |  |  |
Pfizer, Inc. | Option Payments To License Agreement | Maximum |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  | 37,500,000 |  |  |  |  |  |  |
Bayer Collaboration Agreement |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  |  |  |  | $ 17,500,000
Bayer Collaboration Agreement | Research Funding Payments |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Payments received |  | 1,500,000 | $ 3,000,000 |  |  |  |  |  |
Bayer Collaboration Agreement | Research Funding Payments | Scenario Forecast | Subsequent Event |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  | $ 12,000,000 |  |  |  |
Bayer Collaboration Agreement | Development Milestone Payments |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Payments received |  | 0 |  |  |  |  |  |  |
Bayer Collaboration Agreement | Development Milestone Payments | Maximum |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  |  |  |  | 197,500,000
Bayer Collaboration Agreement | Sales Based Milestone Payments |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Payments received |  | 0 |  |  |  |  |  |  |
Bayer Collaboration Agreement | Sales Based Milestone Payments | Maximum |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  |  |  |  |  |  |  |  | $ 490,000,000
Genentech, Inc. and F. Hoffman-La Roche Ltd. |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Payments received | $ 34,500,000 |  |  |  |  |  |  |  |
Additional upfront non-refundable amount received under previous agreement | $ 11,000,000 |  |  |  |  |  |  |  |
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Regulatory Milestone Related to Marketing Approvals |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  | 52,500,000 |  |  |  |  |  |  |
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Development Milestone Payments | Maximum |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  | 44,000,000 |  |  |  |  |  |  |
Genentech, Inc. and F. Hoffman-La Roche Ltd. | Commercial Milestones |  |  |  |  |  |  |  |  |
Research Collaboration And License Agreements [Line Items] |  |  |  |  |  |  |  |  |
Contract revenue receivable if milestones achieved |  | 60,000,000 |  |  |  |  |  |  |
Payments received |  | $ 0 |  |  |  |  |  |  |

X
- Definition Additional upfront non-refundable amount received under previous agreement. + References No definition available. + Details
Name: | arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement
Namespace Prefix: | arvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaboration contract asset and other assets. + References No definition available. + Details
Name: | arvn_CollaborationContractAssetAndOtherAssets
Namespace Prefix: | arvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Direct and incremental costs incurred to obtain the contract. + References No definition available. + Details
Name: | arvn_DirectAndIncrementalCostsIncurredToObtainTheContract
Namespace Prefix: | arvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Research collaboration and license agreements. + References No definition available. + Details
Name: | arvn_ResearchCollaborationAndLicenseAgreementsLineItems
Namespace Prefix: | arvn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_RegulatoryAndSalesBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_CollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_RegulatoryMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_DevelopmentMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_OptionPaymentsToLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=arvn_BayerAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arvn_CommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |